KANSAS CITY, Mo., - Jurox Inc. subsidiary to the Australian headquartered animal health company, has appointed Jim Van Proosdy as Chief Operations Officer.
Mr. Van Proosdy joins Jurox with over 24 years’ experience in animal health holding leadership roles in companies such as Boehringer Ingelheim, MAI Animal Health / Genesis Industries, Merial, Bayer and most recently as Vice President of US Sales for Virbac.
The appointment of a new Operations Chief signifies a major addition of leadership and experience for the Kansas City based start-up. “Jim’s proven record of leadership, deliverability and operational management will no doubt become an integral part of solidifying our position in North America,” remarked JJ O’Brien, Chief Executive of Jurox Inc.
Mr. Van Proosdy will head up US commercial operations by leading the strategic directives in the firm’s focus area of anesthesia and continuing the marketing efforts for Alfaxan® (alfaxalone 10mg/mL) intravenous injectable anesthetic for cats and dogs. “Jurox has a bright future, I look forward to building a strong US portfolio in the coming years through the support of our Australian research group.”
Jurox is an established family owned veterinary pharmaceutical company that manufactures and markets the product Alfaxan® (alfaxalone 10mg/mL) in the US. Marketing over 120 proprietary products in the Australia domestic market, the firm chose to base its US operations in Kansas City. Jurox invests 15% of revenue into research and development and the Company is GMP certified under MRA, US FDA inspected and NATA recognized for compliance with the OECD Principles of Good Laboratory Practice and ISO17025 Laboratory Accredited.